|View printer-friendly version|
|Emergent BioSolutions Chairman and CEO Fuad El-Hibri Recognized as Outstanding International Business Leader|
|ROCKVILLE, Md., Mar 11, 2010 (BUSINESS WIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that Fuad
El-Hibri, its chairman and chief executive officer, has been named by
the World Trade Center Institute (WTCI) as one of Maryland's outstanding
international business leaders. Celebrating the spirit of global
ambition and excellence in international leadership, WTCI presents the
Maryland International Leadership Awards annually to leaders within the
state who exemplify entrepreneurial spirit, innovation, and global reach.
Mr. El-Hibri stated, "Across the globe and on a daily basis, the Emergent team lives out the company mission of protecting life - a commitment to make meaningful contributions to address unmet medical needs especially in underserved markets. It is an honor to be recognized for the work that we do and to receive this award on behalf of the team."
"Mr. El-Hibri recognizes the importance of global markets as key to future growth. WTCI is pleased to showcase Mr. El-Hibri and Emergent BioSolutions' many achievements and is honored to name him as one of Maryland's 2010 International Business Leadership Award winners," said Deborah M. Kielty, president and executive director of the World Trade Center Institute.
WTCI was established in Baltimore in 1989 as a non-profit membership organization to help connect Maryland to the globe. It is the region's premier private sector international business partner and a member of the World Trade Center Association, a family of 300 centers located in vibrant business communities around the world.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Emergent's marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent's product pipeline targets infectious diseases and includes programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional information may be found at www.emergentbiosolutions.com.
SOURCE: Emergent BioSolutions Inc.